81 results
S-3
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
the net proceeds from this offering, if any, for general corporate purposes, which may include research and development expenses, working capital … , for general corporate purposes, which may include research and development expenses, working capital and general and administrative expenses. Our
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
assets
Research and development incentives receivables
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Intangible … of revenue
Research and development
General and administrative
Loss from operations
Other income/(expenses)
Interest income
Interest expense
Changes
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
15 May 24
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
Total research and development (R&D) expenses decreased by $1.3 million, or 25%, from $5.3 million in the first quarter of 2023 to $4.0 million …
Research and development incentives receivables
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Intangible assets
Total
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
and Corporate Governance Committee and three meetings of our Research and Development Committee. All of our then Directors attended a minimum of 75 … by Ultragenyx in November 2017. Prior leadership roles have included the head of global research and development at Merck Serono and SVP, Global Development
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
that have issued or in the future issue therefrom, and in each case that are necessary or useful for the research, development, manufacture, use … to comment thereon.
b.ReproNovo, its Affiliates and their Sublicensees shall have the right to publicly disclose research, development and commercial
10-K
pdc7rqtsc4k
27 Mar 24
Annual report
5:20pm
8-K
EX-99.1
m6emkpuc5cc78rwo3le4
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
6-K
EX-99.1
xsgudxxi
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.2
ogb zfc1gqg
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.3
1npo3wqv r3vx0k
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.2
a8d27i
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.1
7hypu1cjdzaal8hazy
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.1
u5r41yps3d4pe
22 Aug 22
Notifies Rubric of Certain Deficiencies in its Notice Purporting to Call a General Meeting of Shareholders
4:06pm
6-K
zxmi renjiynl
9 May 22
Current report (foreign)
8:15am